Access Program Information
This is an expanded access use of Stiripentol in Dravet Syndrome or epileptic
encephalopathies associated with sodium channel mutations who have failed other drugs in an
effort to give them the best chance at seizure control and quality of life. As a treatment
protocol and not a research study, children will only be monitored on a clinical basis for
seizure improvement and side effects predominantly by parent and caregiver report.